Targeting tumor lysis syndrome: new therapeutic options.
Shonkwiler
Erin
E
Saint Luke's Cancer Institute, Kansas City, MO, USA.
D000493:Allopurinol / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D042241:Early Diagnosis; D004630:Emergencies / Q000451:nursing; D006074:Gout Suppressants / Q000627:therapeutic use; D006301:Health Services Needs and Demand; D006801:Humans; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000458:organization & administration*; D011322:Primary Prevention; D006435:Renal Dialysis; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D014503:Urate Oxidase / Q000191:economics / Q000627:therapeutic use
D006074:Gout Suppressants; C469709:rasburicase; D000493:Allopurinol; D014503:Urate Oxidase